Skip to content
Research Article Open access CC BY 3.0

Dexamethasone as a Means Not Only for Controlling Vascular Pain Caused by the Administration of Oxaliplatin Via the Peripheral Vein But Also for Controlling Oxaliplatin-Induced Hypersensitivity Reactions

Yoichiro Yoshida, Seiichiro Hoshino, Naoya Aisu, Hironari Shiwaku, Richiko Beppu, Syu Tanimura, Yuichi Yamashita

Journal of Advances in Medicine and Medical Research · pp. 132–141 · Published 31 Jan 2012

10.9734/BJMMR/2012/918

Abstract

Background and Aims: With the recent development of capecitabine and oxaliplatin (XELOX) therapy, implantation of a Central Venous (CV) port can be now avoided. However, vascular pain occasionally requires switching of the drip infusion route. Some investigators reported that addition of steroids to oxaliplatin drip infusion is useful in controlling vascular pain. However, the pharmacological use of steroids can make oxaliplatin unstable due to the elevation of pH; further, the effectiveness of steroid in this therapy is unknown. This study was undertaken to evaluate the effectiveness of dexamethasone (DEX) for controlling vascular pain caused by the administration of oxaliplatin via the peripheral vein. Study Design: Retrospective study. Place and duration of the Study: Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, between April 2010 and November 2011. Methodology: The study included 69 patients who received XELOX + bevacizumab therapy for advanced or recurrent colorectal cancer. In all the patients, oxaliplatin (130 mg/m2) was administered in combination with DEX (6.6 mg) via the peripheral vein. Results: Vascular pain developed in 47 patients (68.1%), but it was transient. No patients required CV port implantation. Grade 3 or higher hemotoxicity was noted in 14.5% of the patients, and grade 3 or higher nonhematological toxicity was noted in 20.3% of the patients. The response rate was 59.4%. One patient experienced hypersensitivity reactions to oxaliplatin. Conclusions: The recorded response rate combined with the use of DEX suggests that DEX probably does not exert adverse effects on the therapy, ie, it does not affect the stability of oxaliplatin by elevating the pH. DEX may be useful not only for controlling vascular pain caused by the administration of oxaliplatin via the peripheral vein but also for controlling oxaliplatin-induced hypersensitivity reactions.

Oxaliplatin dexamethasone vascular pain hypersensitivity colorectal cancer.

References (32)

  1. 1 Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer [DOI]
  2. 2 FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study [DOI]
  3. 3 Hypersensitivity reactions related to oxaliplatin (OHP) [DOI]
  4. 4 Fatal Microvascular Pulmonary Emboli From Precipitation of a Total Nutrient Admixture Solution [DOI]
  5. 5 Hypersensitivity reactions to oxaliplatin: experience in a single institute [DOI]
  6. 6 Hypersensitivity and idiosyncratic reactions to oxaliplatin [DOI]
  7. 7 Experimental infusion phlebitis: tolerance osmolality of peripheral venous endothelial cells [DOI]
  8. 8 Hypersensitivity Reactions to Oxaliplatin: Cross-Reactivity to Carboplatin and the Introduction of a Desensitization Schedule [DOI]
  9. 9 Hypersensitivity Reactions to oxaliplatin: incidence and management.
  10. 10 Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin [DOI]
  11. 11 Venous Access Ports: Frequency and Management of Complications in Oncology Patients [DOI]
  12. 12 The Pathophysiology of Oxaliplatin-Induced Neurotoxicity [DOI]
  13. 13 Alkaline Hydrolysis of Oxaliplatin—Isolation and Identification of the Oxalato Monodentate Intermediate [DOI]
  14. 14 Hypersensitivity and cross-reactivity to cisplatin and analogues [DOI]
  15. 15 Experimental infusion phlebitis: Tolerance pH of peripheral vein. [DOI]
  16. 16 High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin [DOI]
  17. 17 Hydrolysis of Oxaliplatin—Evaluation of the Acid Dissociation Constant for the Oxalato Monodentate Complex [DOI]
  18. 18 Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan [DOI]
  19. 19 Risk Factors for Oxaliplatin-Induced Hypersensitivity Reactions in Japanese Patients with Advanced Colorectal Cancer [DOI]
  20. 20 Doxorubicin-associated flare reactions.
  21. 21 Methods of preventing vinorelbine-induced phlebitis: an experimental study in rabbits [DOI]
  22. 22 [The incidence of phlebitis in the patients administrated vinorelbine by intravenous bolus injection--a retrospective study].
  23. 23 [Etiology and management of venous pain during intravenous administration of oxaliplatin].
  24. 24 Precipitation of calcium phosphate from parenteral nutrient fluids [DOI]
  25. 25 COMPLICATIONS OF INTRAVENOUS THERAPY: REDUCTION BY BUFFERING OF INTRAVENOUS FLUID PREPARATION [DOI]
  26. 26 Vinorelbine Chemotherapy in Non Small Cell Lung Cancer: Experience in Elderly Patients [DOI]
  27. 27 HYDROCORTISONE IN THE PREVENTION OF TRANSFUSION THROMBOPHLEBITIS [DOI]
  28. 28 Evaluation of the local irritation potential of hypertonic saline–dextran (HSD) in mice and rabbits [DOI]
  29. 29 On the efficacy of low dose prednisolone and heparin sodium in the prevention of infusion thrombophlebitis. A double-blind trial [DOI]
  30. 30 Clinical features of hypersensitivity reactions to oxaliplatin among Chinese colorectal cancer patients [DOI]
  31. 31 Hypersensitivity and cross-reactivity to cisplatin and analogues [DOI]
  32. 32 Heparin, hydrocortisone, and prevention of peripheral infusion thrombophlebitis.

Cited by 23

Evaluation of vascular pain in patients with colorectal cancer receiving peripheral venous chemotherapy with or without oxaliplatin

Taisuke Matsuoka, Yoichiro Yoshida, Naoya Aisu · Scientific Reports · 2019

Can grade 2 neutropenia predict the risk of grade 3 neutropenia in metastatic colorectal cancer patients treated with chemotherapy?

Yoichiro Yoshida, Seiichiro Hoshino, Naoya Aisu · Supportive Care in Cancer · 2014

Administration of chemotherapy via the median cubital vein without implantable central venous access ports: port-free chemotherapy for metastatic colorectal cancer patients

Yoichiro Yoshida, Seiichiro Hoshino, Naoya Aisu · International Journal of Clinical Oncology · 2014

Effect of pH adjustment by mixing steroid for venous pain in colorectal cancer patients receiving oxaliplatin through peripheral vein: a multicenter randomized phase II study (APOLLO)

Taishi Hata, Michitaka Honda, Michiya Kobayashi · Cancer Chemotherapy and Pharmacology · 2015

Pilot study of the early start of chemotherapy after resection of primary colorectal cancer with distant metastases (Pearl Star 01)

Yoichiro Yoshida, Seiichiro Hoshino, Naoya Aisu · World Journal of Surgical Oncology · 2013

Preventive effect of pre-warming, hot compress, and pH adjustment in oxaliplatin-induced venous pain

Hitoshi Kawazoe, Satomi Sumikawa, Kana Nakauchi · International Journal of Clinical Pharmacy · 2017

Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer

Hideki Ohta, Takahiro Hayashi, Sumie Murai · Cancer Chemotherapy and Pharmacology · 2017

Premedication with fast-acting oxycodone hydrochloride hydrate effectively reduced oxaliplatin-induced severe vascular pain

Sayaka Nagao, Makoto Furihata, Kazushi Fukagawa · Journal of Infection and Chemotherapy · 2017

Randomized phase II trial of the prophylactic use of celecoxib for the prevention of oxaliplatin-related peripheral vascular pain in Capeox (YCOG1205)

Yusuke Suwa, Jun Watanabe, Mitsuyoshi Ota · Cancer Chemotherapy and Pharmacology · 2018

Objective evaluation of oxaliplatin-induced vascular pain secondary to peripheral vein administration

Yoichiro Yoshida, Ai Mogi, Naoya Aisu · SpringerPlus · 2016

Showing 10 of 23 known citations — external sources report more than can currently be individually listed.

Related research

Article metrics

Real usage data collected on this platform.

47

Page views

0

PDF downloads

4

Outbound clicks

23

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.